Analysts expect Scinai Immunotherapeutics Ltd. to report revenue of 0.00 for Q4 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 24, came in at 168,000.00.
| Metric | Q4 23 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | 168,000.00 | - | - | - | - | - | - | - | ||
| High Estimate | 0.00 | - | 0.00 | -38,187.67 | -41,430.83 | 125,604.41 | -39,208.56 | -40,530.66 | -38,081.22 | ||
| Low Estimate | 0.00 | - | 0.00 | -41,208.71 | -47,332.81 | 117,672.61 | -46,820.88 | -45,166.98 | -43,034.64 | ||
| Consensus Estimate | 0.00 | - | 0.00 | -39,698.19 | -44,381.82 | 121,638.51 | -43,014.72 | -42,848.82 | -40,557.93 |
Analysts expect Scinai Immunotherapeutics Ltd. to report earnings per share of -60.07 for Q4 23, against a range of -64.41 to -55.73. The most recent reported quarter, Q3 24, came in at 0.02.
| Metric | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.30 | 0.20 | - | -0.01 | 0.02 | - | - | - | - | - | - | - | ||
| High Estimate | -44.26 | -96.51 | -55.73 | - | - | -31.96 | 17.36 | 16.06 | 10.13 | -35.97 | 23.83 | 22.48 | ||
| Low Estimate | -51.76 | -102.99 | -64.41 | - | - | -35.66 | 15.28 | 13.40 | 8.75 | -41.49 | 21.69 | 19.70 | ||
| Consensus Estimate | -48.01 | -99.75 | -60.07 | - | - | -33.81 | 16.32 | 14.73 | 9.44 | -38.73 | 22.76 | 21.09 |